Progress and predictions: AML in 2018

Abstract

The FLT3 inhibitor midostaurin, the antibody-drug conjugate gemtuzumab ozogamicin, CPX-351 (liposomal daunorubicin and cytarabine), and the IDH2 inhibitor enasidenib are among the novel agents approved for use in the clinic this past year. This year, 2018, already has seen the regulatory approval of the BCL2 inhibitor venetoclax in the form of breakthrough designation and the IDH1 inhibitor ivosidenib received full FDA approval. Much remains to be learned about how best to use these drugs to improve patient outcomes and how best to employ and interpret next-generation sequencing to determine measurable residual disease (MRD) levels that can more accurately predict risk of relapse.

Keywords: AML; Acute myeloid leukemia; Enasidenib; FLT3; Gemtuzumab; Histone deacetylase; IDH; Ivosidenib; MRD; Measurable residual disease; Midostaurin; Venetoclax.